SE0004781D0 - A screening assay for antagonists of human leukocyte receptors - Google Patents

A screening assay for antagonists of human leukocyte receptors

Info

Publication number
SE0004781D0
SE0004781D0 SE0004781A SE0004781A SE0004781D0 SE 0004781 D0 SE0004781 D0 SE 0004781D0 SE 0004781 A SE0004781 A SE 0004781A SE 0004781 A SE0004781 A SE 0004781A SE 0004781 D0 SE0004781 D0 SE 0004781D0
Authority
SE
Sweden
Prior art keywords
antagonists
induced
screening assay
human leukocyte
ligand
Prior art date
Application number
SE0004781A
Other languages
English (en)
Inventor
Zhenyi Xu
K M Erik Michaelsson
Leif Petersson
Poul Soerensen
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0004781A priority Critical patent/SE0004781D0/sv
Publication of SE0004781D0 publication Critical patent/SE0004781D0/sv
Priority to JP2002553116A priority patent/JP2004516037A/ja
Priority to CNA01821066XA priority patent/CN1481504A/zh
Priority to CA002436777A priority patent/CA2436777A1/en
Priority to EP01272418A priority patent/EP1344063A1/en
Priority to US10/432,726 priority patent/US20040106160A1/en
Priority to PCT/SE2001/002841 priority patent/WO2002052268A1/en
Priority to RU2003122348/15A priority patent/RU2003122348A/ru
Priority to NO20032458A priority patent/NO20032458L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
SE0004781A 2000-12-22 2000-12-22 A screening assay for antagonists of human leukocyte receptors SE0004781D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0004781A SE0004781D0 (sv) 2000-12-22 2000-12-22 A screening assay for antagonists of human leukocyte receptors
JP2002553116A JP2004516037A (ja) 2000-12-22 2001-12-20 ヒト白血球受容体アンタゴニストのスクリーニング・アッセイ
CNA01821066XA CN1481504A (zh) 2000-12-22 2001-12-20 用于人类白细胞受体拮抗剂的筛选试验方法
CA002436777A CA2436777A1 (en) 2000-12-22 2001-12-20 A screening assay for antagonists of human leukocyte receptors
EP01272418A EP1344063A1 (en) 2000-12-22 2001-12-20 A screening assay for antagonists of human leukocyte receptors
US10/432,726 US20040106160A1 (en) 2000-12-22 2001-12-20 Screening assay for antagonists of human leukocyte receptors
PCT/SE2001/002841 WO2002052268A1 (en) 2000-12-22 2001-12-20 A screening assay for antagonists of human leukocyte receptors
RU2003122348/15A RU2003122348A (ru) 2000-12-22 2001-12-20 Скрининг антагонистов рецепторов лейкоцитов человека
NO20032458A NO20032458L (no) 2000-12-22 2003-05-30 Screeningsanalyse for antagonister av humane leukocytreseptorer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0004781A SE0004781D0 (sv) 2000-12-22 2000-12-22 A screening assay for antagonists of human leukocyte receptors

Publications (1)

Publication Number Publication Date
SE0004781D0 true SE0004781D0 (sv) 2000-12-22

Family

ID=20282361

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0004781A SE0004781D0 (sv) 2000-12-22 2000-12-22 A screening assay for antagonists of human leukocyte receptors

Country Status (9)

Country Link
US (1) US20040106160A1 (sv)
EP (1) EP1344063A1 (sv)
JP (1) JP2004516037A (sv)
CN (1) CN1481504A (sv)
CA (1) CA2436777A1 (sv)
NO (1) NO20032458L (sv)
RU (1) RU2003122348A (sv)
SE (1) SE0004781D0 (sv)
WO (1) WO2002052268A1 (sv)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113981031A (zh) * 2021-11-01 2022-01-28 山西中医药大学 一种新型t细胞功能检测方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201104950D0 (en) * 2011-03-24 2011-05-11 Univ Birmingham Immune assay
CN104977237B (zh) * 2015-07-01 2018-02-23 北京理工大学 一种原位检测单个活细胞内细胞器中co2生成速率的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4535893A (en) * 1992-06-15 1994-01-04 Regents Of The University Of California, The Screening assay for the identification of immunosuppressive drugs
WO1994014065A1 (en) * 1992-12-14 1994-06-23 Dana-Farber Cancer Institute, Inc. Methods for identifying and using immunosuppressant compounds
DE69905049T2 (de) * 1998-07-13 2003-11-20 Cellomics Inc Auf zellen basiertes screening-system
JP2002533464A (ja) * 1998-12-28 2002-10-08 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント プテリジン誘導体の免疫抑制作用
FR2788602B1 (fr) * 1999-01-20 2002-06-07 Inst Nat Sante Rech Med Procede de criblage utile pour identifier des ligands potentiels pour un recepteur capable de s'internaliser
US6642249B2 (en) * 2001-07-04 2003-11-04 Active Biotech Ab Immunomodulating compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113981031A (zh) * 2021-11-01 2022-01-28 山西中医药大学 一种新型t细胞功能检测方法

Also Published As

Publication number Publication date
CN1481504A (zh) 2004-03-10
NO20032458D0 (no) 2003-05-30
NO20032458L (no) 2003-06-18
WO2002052268A1 (en) 2002-07-04
JP2004516037A (ja) 2004-06-03
RU2003122348A (ru) 2005-01-27
CA2436777A1 (en) 2002-07-04
US20040106160A1 (en) 2004-06-03
EP1344063A1 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
BRPI0410933A (pt) novos antagonistas do receptor p2x7 e seu uso
LV12639B (lv) Bifenilsulfonamidi ka duali angiotenzina un endotelina receptoru antagonisti
BR0110079A (pt) Combinação de compostos orgânicos
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
NO975598L (no) Monoklonale ape-antistoffer som er spesifikke for primatiserte humane B7.1- og/eller B7.2-former, samt farmasöytiske sammensetninger
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
TR200001942T2 (tr) Opioid agonist/antagonist kombinasyonlar
HUP9603298A3 (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
ATE226247T1 (de) Menschliche neuronale nikotin-acetylcholin- rezeptor-verbindungen und methoden ihres einsatzes
BR9910144A (pt) Antagonistas de receptores de quimiocinas e seu uso
DE69429861T2 (de) Endothelin-rezeptor-antagonisten
NO20012194L (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
HUP9904672A2 (hu) Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
NO991926L (no) Oppl°selige lymfotoksin-<beta> reseptorer, anti-lymfotoksin-reseptor antistoff samt anti-lymfotoksin-ligand antistoff som terapeutiske midler til behandling av immunologiske sykdommer
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
DK1240326T3 (da) Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
SE0004781D0 (sv) A screening assay for antagonists of human leukocyte receptors
BR9815335A (pt) Uso de antagonistas de receptor de endotelina.
NO20001548L (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
ATE341324T1 (de) Endothelin rezeptor antagonisten
DE59808297D1 (de) Endothelin antagonist und betarezeptorenblocker als kombinationspräparate